Literature DB >> 14534535

Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL.

Viqar Syed1, Shuk-Mei Ho.   

Abstract

Progesterone (P4) has been implicated as a protective factor for epithelial ovarian cancers, yet little is known about its mechanism of action. We previously reported that pregnancy-equivalent doses of P4 inhibited the growth of normal and malignant human ovarian surface epithelial (HOSE) cells. Here, we investigated how P4-induced cell death in two immortalized normal (HOSE 642, HOSE 12-12) and two malignant (OVCA 429, OVCA 432) HOSE cell lines. The exposure of HOSE or OVCA cell cultures to 10(-6) M P4 induced time-dependent increases in early and late apoptotic cells and activation of caspase-8 and -3, but not that of caspase-9. A general caspase inhibitor Z-VAD effectively blocked the P4-induced cell death in a dose-dependent manner. Comparable levels of Fas mRNA and protein were expressed in HOSE and OVCA cell lines, and these levels were unaffected by P4. In contrast, levels of FasL mRNA and protein were higher in OVCA cells than in HOSE cells. Interestingly, the hormone enhanced levels of FasL mRNA and protein in HOSE cells, but lowered their levels in OVCA cells. The exposure of HOSE or OVCA cells to an activating anti-Fas antibody induced cell loss, whereas treatment of cells with a blocking anti-FasL antibody reduced the P4-induced cell loss. Cotreatment of cells with the activating anti-Fas antibody and P4 produced additive effects on cell loss. These results reveal for the first time that P4 induces apoptosis in HOSE and OVCA cells via activation of a caspase-8-initiated Fas/FasL signaling pathway. They also demonstrate differential P4-regulation of FasL expression between HOSE and OVCA cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534535     DOI: 10.1038/sj.onc.1206828

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  Birth spacing and maternal risk of invasive epithelial ovarian cancer in a Swedish nationwide cohort.

Authors:  Inkyung Baik; Mats Lambe; Qin Liu; Lucy Chie; Sven Cnattingius; Lorelei A Mucci; Tomas Riman; Anders Ekbom; Hans-Olov Adami; Chung-Cheng Hsieh
Journal:  Cancer Causes Control       Date:  2008-05-29       Impact factor: 2.506

Review 2.  Progesterone action in breast, uterine, and ovarian cancers.

Authors:  Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2015-01-13       Impact factor: 5.098

3.  Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events.

Authors:  Nathan J Charles; Peter Thomas; Carol A Lange
Journal:  Horm Cancer       Date:  2010-08       Impact factor: 3.869

4.  Norsolorinic acid from Aspergillus nidulans inhibits the proliferation of human breast adenocarcinoma MCF-7 cells via Fas-mediated pathway.

Authors:  Clay C C Wang; Yi-Ming Chiang; Po-Lin Kuo; Jiunn-Kae Chang; Ya-Ling Hsu
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-03-16       Impact factor: 4.080

5.  Estrous cycle modulates ovarian carcinoma growth.

Authors:  Guillermo N Armaiz-Pena; Lingegowda S Mangala; Whitney A Spannuth; Yvonne G Lin; Nicholas B Jennings; Alpa M Nick; Robert R Langley; Rosemarie Schmandt; Susan K Lutgendorf; Steven W Cole; Anil K Sood
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

Review 6.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

7.  Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.

Authors:  Caroline H Diep; Nathan J Charles; C Blake Gilks; Steve E Kalloger; Peter A Argenta; Carol A Lange
Journal:  Cell Cycle       Date:  2013-04-10       Impact factor: 4.534

8.  Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models.

Authors:  Laura J Mauro; Megan I Seibel; Caroline H Diep; Angela Spartz; Carlos Perez Kerkvliet; Hari Singhal; Elizabeth M Swisher; Lauren E Schwartz; Ronny Drapkin; Siddharth Saini; Fatmata Sesay; Larisa Litovchick; Carol A Lange
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

9.  The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro.

Authors:  P M O'Brien; M J Davies; J P Scurry; A N Smith; C A Barton; M J Henderson; D N Saunders; B S Gloss; K I Patterson; J L Clancy; V A Heinzelmann-Schwarz; Rajmohan Murali; R A Scolyer; Y Zeng; E D Williams; L Scurr; A Defazio; D I Quinn; C K W Watts; N F Hacker; S M Henshall; R L Sutherland
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

10.  Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

Authors:  Minh Tung Phung; Alice W Lee; Anna H Wu; Andrew Berchuck; Kathleen R Cho; Daniel W Cramer; Jennifer Anne Doherty; Marc T Goodman; Gillian E Hanley; Holly R Harris; Karen McLean; Francesmary Modugno; Kirsten B Moysich; Bhramar Mukherjee; Joellen M Schildkraut; Kathryn L Terry; Linda J Titus; Susan J Jordan; Penelope M Webb; Malcolm C Pike; Celeste Leigh Pearce
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-02-22       Impact factor: 4.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.